FDA warned website Ketamine Store for selling unapproved, misbranded ketamine liquid and compounded products online without prescriptions.
What happened
FDA reviewed the website www.ketaminestore.org on February 26, 2026, rather than doing an inspection. The review found ketamine products offered for sale to U.S. consumers, including "KETAMINE LIQUID," "Ketamine Troches" and "KETAMINE NASAL SPRAY," marketed with claims about treating depression, anxiety and pain. FDA says none of these have an approved application, the compounded versions were sold without prescriptions for individual patients, and the labeling lacks adequate directions for use.
What FDA found
The company sells ketamine liquid as a drug without an FDA-approved application for it.
FD&C Act sections 505(a) and 301(d) (21 U.S.C. 355(a), 331(d))It sells compounded ketamine troches and nasal spray without prescriptions for identified patients and is not a registered outsourcing facility, so it does not qualify for the compounding exemptions.
FD&C Act sections 503A and 503B (21 U.S.C. 353a, 353b)The product labeling does not carry adequate directions for use, so the drugs are misbranded.
FD&C Act section 502(f)(1) (21 U.S.C. 352(f)(1)); 21 CFR 201.5, 201.115(a)The company offers prescription drugs for sale without requiring a prescription, which misbrands them while held for sale.
FD&C Act sections 503(b)(1) and 301(k) (21 U.S.C. 353(b)(1), 331(k))
What FDA wants
FDA tells the company to stop offering any unapproved and misbranded drugs to U.S. consumers, and to send a written response within 15 business days describing the corrections, how it will prevent repeat violations, and supporting documents.
Who should pay attention
- online pharmacies and websites selling compounded ketamine
- ketamine and telehealth clinics that refer patients to online sellers
- compounding pharmacies that supply products sold without patient prescriptions
This is a summary. Read the original letter on fda.gov.